J. Safra Sarasin Holding AG Purchases 26,463 Shares of Pfizer Inc. $PFE

J. Safra Sarasin Holding AG lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 22.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 143,246 shares of the biopharmaceutical company’s stock after buying an additional 26,463 shares during the period. J. Safra Sarasin Holding AG’s holdings in Pfizer were worth $3,472,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC grew its holdings in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC boosted its position in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the period. Merit Financial Group LLC grew its stake in shares of Pfizer by 24.1% during the first quarter. Merit Financial Group LLC now owns 158,871 shares of the biopharmaceutical company’s stock valued at $4,026,000 after buying an additional 30,904 shares during the last quarter. RFG Advisory LLC increased its holdings in shares of Pfizer by 41.2% in the first quarter. RFG Advisory LLC now owns 70,409 shares of the biopharmaceutical company’s stock worth $1,784,000 after buying an additional 20,546 shares during the period. Finally, Apella Capital LLC lifted its stake in shares of Pfizer by 6.5% in the 1st quarter. Apella Capital LLC now owns 22,602 shares of the biopharmaceutical company’s stock valued at $573,000 after acquiring an additional 1,374 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of analyst reports. Bank of America lifted their price target on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. UBS Group reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday. Morgan Stanley increased their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $28.29.

Pfizer Stock Down 0.5%

Shares of Pfizer stock opened at $27.08 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a market cap of $153.94 billion, a P/E ratio of 14.40, a PEG ratio of 0.88 and a beta of 0.55. The company’s fifty day simple moving average is $24.62 and its two-hundred day simple moving average is $24.14.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the firm posted $0.60 EPS. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.